GRI Bio, Inc. (GRI) · Nov 4, 2026 · Other events

GRI Bio annual meeting approves 25% equity-plan increase

546,529-share plan increase — 546,529 added shares; approximately 25% of 2.19M shares outstanding

GRI Bio’s annual meeting approved a major equity-plan expansion, extending awards through 2036 while increasing future dilution capacity.

GRI Bio is a clinical-stage biotech advancing GRI-0621 for idiopathic pulmonary fibrosis after Phase 2a data, while still needing substantial capital to move toward Phase 2b.

The main outcome is authorization for a materially larger equity-award pool. Stockholders approved adding 546,529 shares to the 2018 Equity Incentive Plan and extending its evergreen feature through January 1, 2036. 〔0〕 Against only 2.19 million shares outstanding, the increase is roughly 25% of the current share count—but these are potential future awards, not immediate share issuance.

That is useful for retaining a cash-constrained biotech workforce, but the trade-off is greater dilution capacity. The plan approval was already disclosed in the September 28, 2026 proxy and therefore was largely anticipated; the new information is that the proposal passed, not a change in the company’s clinical or financing trajectory.

The governance portion is routine and the filing does not show vote tallies. It confirms the director elections and plan approval, with 926,474 shares represented at the meeting, equal to approximately 42.37% of eligible shares. 〔1〕 Without FOR, AGAINST, and abstention counts, shareholder support cannot be judged beyond the fact of approval.

Bottom line: This clears a planned compensation authorization rather than advancing the drug pipeline. It modestly worsens the future dilution setup, but does not materially rewrite GRI Bio’s operating story today.

Original filing on SEC EDGAR

GRI Bio annual meeting approves 25% equity-plan increase | GRI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.